Phone: 888-558-5227

651-644-8424

Email: getinfo@lktlabs.com

888-558-7329 Fax:

Web: lktlabs.com

Product Information

Product ID P3540

CAS No. 372196-77-5

Chemical Name

Synonym PIK-75 HCl

Formula C₁₆H₁₄BrN₅O₄S·HCl

Formula Wt. 488.74 Melting Point 221-223°C

Purity ≥98%

Solubility Soluble in DMSO(4mg/mL), DMF

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

Description PIK-75 is an inhibitor of p110α PI3K that exhibits anticancer and anti-inflammatory activities. In breast cancer cells, PIK-75

inhibits cell motility and adhesion in vitro and in vivo. PIK-75 also enhances glucose-induced insulin secretion. Additionally, PIK

-75 inhibits production of TNF-α, IL-6, E-selectin, ICAM-1, and VCAM-1, preventing monocyte-endothelial cell adhesion.

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
P3540	5 mg	\$65.40
P3540	25 mg	\$261.60
P3540	100 mg	\$817.50

References Buchanan CM, Dickson JM, Lee WJ, et al. Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One. 2013 Aug 1;8(8):e71337. PMID: 23936502.

> Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, et al. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic 8-cells. PLoS One. 2012;7(10):e47381. PMID: 23077605.

Smirnova T, Zhou ZN, Flinn RJ, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 2012 Feb 9;31(6):706-15. PMID: 21725367.

Dagia NM, Agarwal G, Kamath DV, et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol. 2010 Apr;298(4):C929-41. PMID: 20089935.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.